Influence of previous physical activity on the outcome of patients treated by thrombolytic therapy for stroke.
Physical activity prevents stroke and is associated with less severe strokes. The neuroprotective effect in patients treated with intravenous (i.v.) recombinant tissue plasminogen activator (rt-PA), remains uncertain. We aimed at evaluating the relationship between previous physical activity and outcomes in stroke patients treated with i.v. rt-PA. OPHELIE-SPORT was a prospective observational multicenter study conducted in French and Japanese stroke patients treated with i.v. rt-PA. We evaluated the presence, weekly duration (<2, 2-5, >5 h) and intensity (light, moderate, heavy) of previous leisure-time physical activity according to standardized criteria. The primary end-point was an excellent outcome [modified Rankin Scale (mRS) 0-1 or similar to the pre-stroke mRS] after 3 months. Secondary end-points were good outcome (mRS 0-2 or similar to the pre-stroke mRS), and death. Of 519 patients, 74 (14.3 %) had regular physical activity before stroke. They were 14 years younger (p < 0.001), treated 25 min earlier (p = 0.004) and more likely to be men, free of pre-stroke handicap (mRS = 0), atrial fibrillation, arterial hypertension, and diabetes mellitus. National Institutes of Health Stroke Scale scores, at baseline (p = 0.183) and 24 h later (p = 0.203), did not differ between patients with and without physical activity. After adjustment on confounders, there was no association between previous leisure-time physical activity and outcome. Outcomes 3 months after treatment of cerebral ischaemia with i.v. rt-PA are not influenced by previous physical activity.
Department of Neurology, Stroke Centre, Lille University Hospital, Lille, France.|INSERM U 1171, University of Lille, Lille, France.|STROKAVENIR Network, 59000, Lille, France.
Amélie
A
Decourcelle
Department of Neurology, Stroke Centre, Lille University Hospital, Lille, France.|INSERM U 1171, University of Lille, Lille, France.|STROKAVENIR Network, 59000, Lille, France.
Solène
S
Moulin
STROKAVENIR Network, 59000, Lille, France.|Department of Neurology, Stroke Center, University of Bordeaux, Bordeaux, France.
Igor
I
Sibon
Department of Cerebrovascular Medicine and Neurology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.|Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kei
K
Murao
STROKAVENIR Network, 59000, Lille, France.|Department of Neurology, Stroke Unit, University of Rennes, Rennes, France.
Thomas
T
Ronzière
STROKAVENIR Network, 59000, Lille, France.|Department of Neurology, Amiens University Hospital, Amiens, France.
Olivier
O
Godefroy
STROKAVENIR Network, 59000, Lille, France.|Department of Neurology, Stroke Center, University of Bordeaux, Bordeaux, France.
Mathilde
M
Poli
Department of Neurology, Stroke Centre, Lille University Hospital, Lille, France.|INSERM U 1171, University of Lille, Lille, France.|STROKAVENIR Network, 59000, Lille, France.
Charlotte
C
Cordonnier
STROKAVENIR Network, 59000, Lille, France.|Department of Neurology, Stroke Center, University of Bordeaux, Bordeaux, France.
Sharmila
S
Sagnier
STROKAVENIR Network, 59000, Lille, France.|Department of Neurology, Stroke Unit, University of Rennes, Rennes, France.
Veronica
V
Lassalle
Department of Cerebrovascular Medicine and Neurology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.|Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yasushi
Y
Okada
STROKAVENIR Network, 59000, Lille, France.|Department of Neurology, Stroke Centre, Sainte-Anne Hospital, University Paris Descartes, Sorbonne Paris Cité, INSERM UMR S783, Paris, France.
Jean-Louis
JL
Mas
INSERM U 1171, University of Lille, Lille, France.|STROKAVENIR Network, 59000, Lille, France.|Pharmacological Department, Lille University Hospital, Lille, France.
Régis
R
Bordet
Department of Neurology, Stroke Centre, Lille University Hospital, Lille, France. didier.leys@univ-lille2.fr.|INSERM U 1171, University of Lille, Lille, France. didier.leys@univ-lille2.fr.|STROKAVENIR Network, 59000, Lille, France. didier.leys@univ-lille2.fr.
Didier
D
Leys
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000188:drug therapy / Q000517:prevention & control; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000502:physiology*; D017063:Outcome Assessment, Health Care; D020521:Stroke / Q000188:drug therapy / Q000517:prevention & control; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000494:pharmacology*
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator
Cerebral ischaemia; Physical exercise; Preconditioning; Stroke; Thrombolysis